ABLYNX WILL ANNOUNCE HALF YEAR RESULTS FOR 2010 WITH WEBCAST
(Thomson Reuters ONE) -
GHENT, Belgium, 19 August 2010 - Ablynx [Euronext Brussels: ABLX] plans to
announce its half year results for 2010 on 25 August 2010 after market closure.
Dr Edwin Moses, CEO and Chairman of Ablynx, will host a conference call webcast
during which the half year results for 2010 will be presented, followed by a Q&A
session. This event will be held on Thursday, 26 August 2010 at 4.00 p.m. CET.
The conference call will be webcast live and can be accessed through the home
page of the Ablynx website (www.ablynx.com). Shortly thereafter, a replay
version of the webcast will be accessible on our website under Investor
Relations>Newsroom>Events and Presentations:
http://www.ablynx.com/investorrelations/english/newsroom_eventsandpresentations.
php.
- ends -
About Ablynx [Euronext Brussels: ABLX] - http://www.ablynx.com
Founded in 2001 in Ghent, Belgium, Ablynx is a biopharmaceutical company focused
on the discovery and development of Nanobodies, a novel class of therapeutic
proteins based on single-domain antibody fragments, for a range of serious and
life-threatening human diseases. The Company currently has over 240 employees.
Ablynx completed a successful IPO on Euronext Brussels [ABLX] on 7 November
2007 and raised ?50 million through an SPO in March 2010.
Ablynx is developing a portfolio of Nanobody-based therapeutics in a number of
major disease areas, including inflammation, thrombosis, oncology and
Alzheimer's disease. Ablynx now has over 25 programmes in its therapeutic
pipeline including four Nanobodies in clinical development. So far, Nanobodies
have been successfully generated against more than 220 different protein targets
including several complex targets such as chemokines, GPCRs, ion channels and
viruses, which are typically very difficult to address with conventional
monoclonal antibodies. Efficacy data have been obtained in 35 in vivo models for
Nanobodies against a range of different targets.
Ablynx has an extensive patent position in the field of Nanobodies for
healthcare applications. It has exclusive and worldwide rights to more than 130
families of granted patents and pending patent applications, including the
Hamers patents covering the basic structure, composition, preparation and uses
of Nanobodies.
For more information, please contact Ablynx:
Dr. Edwin Moses
Chairman and CEO
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193 / +32 (0)473 39 50 68
e: edwin.moses(at)ablynx.com
Eva-Lotta Allan
Chief Business Officer
t: +32 (0)9 262 00 75
m: +32 (0)475 78 36 21 / +44 (0)7990 570 900
e:eva-lotta.allan(at)ablynx.com
Wim Ottevaere
Chief Financial Officer
t: +32 (0)9 262 00 08
e:wim.ottevaere(at)ablynx.com
[HUG#1439039]
Complete version of the press release:
http://hugin.info/137912/R/1439039/383468.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
All reproduction for further distribution is prohibited.
Source: Ablynx via Thomson Reuters ONE
Unternehmensinformation / Kurzprofil:
Datum: 19.08.2010 - 18:01 Uhr
Sprache: Deutsch
News-ID 39842
Anzahl Zeichen: 0
contact information:
Town:
Ghent
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 177 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"ABLYNX WILL ANNOUNCE HALF YEAR RESULTS FOR 2010 WITH WEBCAST"
steht unter der journalistisch-redaktionellen Verantwortung von
Ablynx (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
